MA28435B1 - Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4 - Google Patents

Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4

Info

Publication number
MA28435B1
MA28435B1 MA29276A MA29276A MA28435B1 MA 28435 B1 MA28435 B1 MA 28435B1 MA 29276 A MA29276 A MA 29276A MA 29276 A MA29276 A MA 29276A MA 28435 B1 MA28435 B1 MA 28435B1
Authority
MA
Morocco
Prior art keywords
compounds
receptor agonists
carboxamide compounds
indazole
indazole carboxamide
Prior art date
Application number
MA29276A
Other languages
English (en)
Inventor
Daniel Marquess
Seok-Ki Choi
Paul R Fatheree
Roland Gendron
Adam A Goldblum
Daniel D Long
S Derek Turner
Jyanwei Liu
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28435(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MA28435B1 publication Critical patent/MA28435B1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention a trait à des composés d'indazole-carboxamide agoniste de récepteur 5-HT4. L'invention a également trait à des compositions pharmaceutiques comprenant de tels composés, à des procédés d'utilisation de tels composés pour le traitement de maladies associées à l'activité de récepteur 5-HT4, et à des procédés et des intermédiaires utiles pour la préparation de tels composés.
MA29276A 2004-02-18 2006-08-18 Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4 MA28435B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54570204P 2004-02-18 2004-02-18

Publications (1)

Publication Number Publication Date
MA28435B1 true MA28435B1 (fr) 2007-02-01

Family

ID=34886184

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29276A MA28435B1 (fr) 2004-02-18 2006-08-18 Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4

Country Status (16)

Country Link
US (3) US7351704B2 (fr)
EP (1) EP1718643A1 (fr)
JP (1) JP2007523175A (fr)
KR (1) KR20060132727A (fr)
CN (1) CN1922175A (fr)
AR (1) AR047681A1 (fr)
AU (1) AU2005214368A1 (fr)
BR (1) BRPI0507791A (fr)
CA (1) CA2553696A1 (fr)
IL (1) IL177059A0 (fr)
MA (1) MA28435B1 (fr)
NO (1) NO20064156L (fr)
RU (1) RU2006133320A (fr)
TW (1) TW200533348A (fr)
WO (1) WO2005080389A1 (fr)
ZA (1) ZA200606479B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7399862B2 (en) * 2004-11-05 2008-07-15 Theravance, Inc. 5-HT4 receptor agonist compounds
WO2006052889A2 (fr) * 2004-11-05 2006-05-18 Theravance, Inc. Composes de quinolinone-carboxamide
CA2588037A1 (fr) * 2004-12-22 2006-06-29 Theravance, Inc. Composes d'indazole-carboxamide
WO2006088988A1 (fr) * 2005-02-17 2006-08-24 Theravance, Inc. Forme cristalline d'un compose d'indazole/carboxamide
CN101163701A (zh) * 2005-03-02 2008-04-16 施万制药 作为5-ht4受体激动剂的喹啉酮化合物
EP1902053B1 (fr) * 2005-06-07 2011-01-12 Theravance, Inc. Composes de benzoimidazolone-carboxamide en tant qu'agonistes du recepteur 5-ht4
US20080262040A1 (en) * 2005-10-25 2008-10-23 Smithkline Beecham Corporation Chemical Compounds
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
CN101384588B (zh) * 2006-02-16 2011-08-31 施万制药 制备5-ht4受体激动剂化合物的中间体的方法
KR100812499B1 (ko) * 2006-10-16 2008-03-11 이도훈 항경련제
WO2008101728A1 (fr) * 2007-02-23 2008-08-28 K.H.S. Pharma Holding Gmbh Procédé de production d'esters d'azoniaspironortropine et de composés nortropane-3-one
EP2241567A4 (fr) * 2008-02-13 2011-11-09 Eisai R&D Man Co Ltd Dérivé de bicycloamine
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
WO2011092290A1 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de pyrazolo[5,1-b] utilisés en tant qu'antagonistes du récepteur de crf-1
EP2531490B1 (fr) 2010-02-02 2014-10-15 Novartis AG Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
JP6023926B2 (ja) * 2010-02-12 2016-11-09 株式会社ＡｓｋＡｔ 認知症治療のための５−ｈｔ４受容体アゴニスト
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
KR20140041519A (ko) * 2011-06-07 2014-04-04 다이닛본 스미토모 세이야꾸 가부시끼가이샤 인다졸-유도체 및 피롤로피리딘-유도체 및 그의 약제학적 용도
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
JP2014133739A (ja) * 2012-12-12 2014-07-24 Dainippon Sumitomo Pharma Co Ltd インダゾール誘導体またはピロロピリジン誘導体からなる医薬
RS60804B1 (sr) * 2014-08-16 2020-10-30 Suven Life Sciences Ltd Proces proizvodnje 1-izopropil-3-{5-[1-(3-metoksipropil)piperidin-4-il]-[1,3,4]oksadiazol-2-il}-1h-indazol oksalata u velikom obimu
CN112805282A (zh) * 2019-09-12 2021-05-14 广东东阳光药业有限公司 吲唑-甲酰胺衍生物及其用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321378A (en) 1979-01-16 1982-03-23 Delalande S.A. 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
HU895334D0 (en) 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
US4948803A (en) 1986-11-21 1990-08-14 Glaxo Group Limited Medicaments for treatment on prevention of withdrawal syndrome
GB8701022D0 (en) 1987-01-19 1987-02-18 Beecham Group Plc Treatment
US5223511A (en) 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
IT1231413B (it) 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
IT1226389B (it) 1988-07-12 1991-01-15 Angeli Inst Spa Nuovi derivati ammidinici e guanidinici
US5017573A (en) 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
EP0410509A1 (fr) 1989-07-25 1991-01-30 Duphar International Research B.V Indazole-1H-carboxamides-3 substitués
JPH045289A (ja) 1990-04-24 1992-01-09 Hokuriku Seiyaku Co Ltd アミド化合物
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
HU211081B (en) 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
CA2097815C (fr) 1990-12-28 2001-04-17 Fumio Suzuki Derive de la quinoline
CA2116024A1 (fr) 1991-08-20 1993-03-04 Francis David King Antagonistes des recepteurs 5-ht4
US5552398A (en) 1991-09-12 1996-09-03 Smithkline Beecham P.L.C. Azabicyclic compounds as 5-HT4 receptor antagonists
MX9305947A (es) 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
WO1994012497A1 (fr) 1992-11-20 1994-06-09 Taisho Pharmaceutical Co., Ltd. Compose heterocyclique
TW251287B (fr) 1993-04-30 1995-07-11 Nissei Co Ltd
GB9310582D0 (en) 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
AU679336B2 (en) 1994-02-28 1997-06-26 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
US5864039A (en) 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
CA2160420A1 (fr) 1994-10-20 1996-04-21 Haruhiko Kikuchi Agonistes du recepteur 5-ht4
JP3829880B2 (ja) 1994-12-27 2006-10-04 大正製薬株式会社 化学中間体
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
US5654320A (en) 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
EP0829474B1 (fr) 1995-05-31 2003-04-09 Nisshin Seifun Group Inc. Derives de l'indazole a groupe amino monocyclique
ES2109190B1 (es) 1996-03-22 1998-07-01 Univ Madrid Complutense Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
IT1291569B1 (it) 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
TW548103B (en) 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US5914405A (en) 1997-10-07 1999-06-22 Eli Lilly And Company Process for preparing 3-substituted indazoles
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
FR2769915B1 (fr) 1997-10-21 2000-10-13 Synthelabo Derives d'indazole tricycliques, leur preparation et leur application en therapeutique
IT1298271B1 (it) 1998-02-18 1999-12-20 Boehringer Ingelheim Italia Esteri ed ammidi dell'acido 2-oxo-2,3-diidro-benzimidazol-1- carbossilico
EP1076055B1 (fr) 1998-04-28 2004-11-24 Dainippon Pharmaceutical Co., Ltd. Derives de 1- (1-substituee-4-piperidinyle)methyle]-4-piperidine, procede de production de ceux-ci, compositions medicinales contenant ces composes et intermediaires de ces composes
AU758807B2 (en) 1998-09-10 2003-03-27 F. Hoffmann-La Roche Ag Dihydrobenzodioxine carboxamide and ketone derivatives as 5-HT4 receptor antagonists
TW570920B (en) 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
FR2792318B1 (fr) 1999-04-16 2001-06-15 Synthelabo Derives d'indazole, leur preparation et leur application en therapeutique
EP1173168A2 (fr) 1999-04-28 2002-01-23 Respiratorius AB Un compose pour l'utilisation d'un medicament destine au traitement de troubles de contraction bronchique
ES2154605B1 (es) 1999-09-14 2001-11-16 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
IT1313625B1 (it) 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
IT1313660B1 (it) 1999-10-01 2002-09-09 Dompe Spa Procedimento stereoselettivo per la preparazione di endo-3-amminoazabicicloalcani.
WO2002036113A1 (fr) 2000-11-01 2002-05-10 Respiratorius Ab Composition comprenant des agonistes (5ht-4) et des antagonistes (5ht-2, 5ht-3) recepteurs de la serotonine
US6624162B2 (en) 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP1492789B1 (fr) 2002-04-08 2006-06-07 Pfizer Limited Derives de tropane utilises comme modulateur de ccr5
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
MXPA05003065A (es) 2002-09-20 2005-05-27 Pfizer Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4.
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
MXPA05011270A (es) 2003-04-21 2006-01-24 Pfizer Compuestos de imidazopiridina que tienen actividad agonista del receptor 5-ht4 y actividad antagonista del receptor 5-ht3.
EP1641783B1 (fr) 2003-06-19 2012-03-28 Janssen Pharmaceutica NV Aminosulfonyle substitue 4-(aminomethyle)-piperidine benzamides utilise comme 5ht4-antagonistes
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
KR100738784B1 (ko) 2003-09-03 2007-07-12 화이자 인코포레이티드 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론
BRPI0416813A (pt) 2003-11-24 2007-03-06 Pfizer compostos de ácido quinolonacarboxìlico com atividade agonista do receptor 5-ht4
ES2299995T3 (es) 2004-01-29 2008-06-01 Pfizer, Inc. Derivados de 1-isopropil-2-oxo-1,2-dihidropiridina-3-carboxamida con actividad agonista de receptor 5-ht4.
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7399862B2 (en) * 2004-11-05 2008-07-15 Theravance, Inc. 5-HT4 receptor agonist compounds

Also Published As

Publication number Publication date
NO20064156L (no) 2006-11-10
CA2553696A1 (fr) 2005-09-01
JP2007523175A (ja) 2007-08-16
TW200533348A (en) 2005-10-16
US20050197335A1 (en) 2005-09-08
CN1922175A (zh) 2007-02-28
WO2005080389A1 (fr) 2005-09-01
IL177059A0 (en) 2006-12-10
US20080146807A1 (en) 2008-06-19
US20100261716A1 (en) 2010-10-14
AU2005214368A1 (en) 2005-09-01
AR047681A1 (es) 2006-02-01
EP1718643A1 (fr) 2006-11-08
BRPI0507791A (pt) 2007-07-17
ZA200606479B (en) 2008-01-30
US7351704B2 (en) 2008-04-01
US8044045B2 (en) 2011-10-25
US7674908B2 (en) 2010-03-09
RU2006133320A (ru) 2008-03-27
KR20060132727A (ko) 2006-12-21

Similar Documents

Publication Publication Date Title
MA28435B1 (fr) Composes d&#39;indazole-carboxamide en tant qu&#39;agonistes de recepteur 5-ht4
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l&#39;activité de gpr119
MA28304A1 (fr) Derives d&#39;arylaniline utilise comme agonistes des recepteurs beta2-adrenergiques
MA28660B1 (fr) Composes et compositions en tant que modulateurs de ppar
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA27779A1 (fr) FORME CRISTALLINE D&#39;AGONISTE DE RECEPTEUR β2 ADRENERGIQUE
AP1542A (en) Glucocorticoid receptor modulators.
MA29568B1 (fr) Composes d&#39;azaindazole et methodes d&#39;utilisation desdits composes
MA29088B1 (fr) Composes d&#39;indazole-carboxamide.
MA30339B1 (fr) Azolopyrimidines inhibitrices de l&#39;activite du recepteur cannabinoïde 1
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA38325A2 (fr) Dérivés de benzothiophène et compositions correspondantes en tant qu&#39;agents de dégradation sélectifs des récepteurs des œstrogènes
MA30798B1 (fr) Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1
MA31087B1 (fr) Derives d&#39;amide et d&#39;ester d&#39;indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA31963B1 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d&#39;utilisation
MA31949B1 (fr) Dérivés d&#39;aminotriazole comme agonistes d&#39;alx
TNSN08137A1 (fr) Derives de carboxamides servant d&#39;antagonistes des recepteurs muscariniques
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
BR0104834A (pt) Moduladores de receptores de glucocorticóides
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4
MA31442B1 (fr) 3-(imidazolyl)-pyrazolo [3,4-b]pyridines
DE60120077D1 (de) Modulatoren des Glucocorticoid-Rezeptors
MA31857B1 (fr) N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci
MA29541B1 (fr) Composes benzimidazole-carboxamide utilises comme agonistes du recepteur 5-ht4
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen